The Early-stage NSCLC Panel is NeoGenomics' most focused early-stage lung cancer panel that detects genomic alterations and gene expression in key biomarkers that are believed to be most relevant in diagnosis, therapy selection, prognosis, and clinical trials. The panel includes EGFR (epidermal growth factor receptor), ALK (anaplastic lymphoma kinase), ROS (reactive oxygen species) and PD-L1 (programmed death-ligand 1) reported in a streamlined test report format.
Non Small Cell Lung Cancer
ALK (Anaplastic lymphoma kinase), EGFR (Epidermal growth factor receptor), PD-L1 (Programmed death ligand 1), ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)